Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors ; volume:28 ; number:6 ; day:16 ; month:10 ; year:2024 ; pages:821-834 ; date:11.2024
Molecular diagnosis & therapy ; 28, Heft 6 (16.10.2024), 821-834, 11.2024
- Urheber
-
Oliveira, Douglas V. N. P.
Biskup, Edyta
O’Rourke, Colm J.
Hentze, Julie L.
Andersen, Jesper B.
Høgdall, Claus
Høgdall, Estrid V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40291-024-00740-y
- URN
-
urn:nbn:de:101:1-2501162107262.084723466089
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oliveira, Douglas V. N. P.
- Biskup, Edyta
- O’Rourke, Colm J.
- Hentze, Julie L.
- Andersen, Jesper B.
- Høgdall, Claus
- Høgdall, Estrid V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer